Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United ...

Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company with a market capitalization of $240 million, recently reported that its Chief Scientific Officer, Carter Todd Alfred, sold 5,413 ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...

The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...

Adial Pharmaceuticals (ADIL) announced patent number 12,221,654 was issued on February 11, 2025, by the United States Patent and Trademark ...

Under the terms of the agreement, TG Therapeutics obtains non-exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation ® technology and ExPERT™ platform. In return, ...

Novo Nordisk announced plans for a longer phase III trial testing its investigational obesity drug CagriSema, with regulatory ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

VANCOUVER, British Columbia and SAN FRANCISCO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), a biotechnology company focused on developing best-in-class therapies for autoimmune ...

New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating ...